DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Category ADMA

Adma Biologics

ADMA Biologics: How Margin Expansion, FDA-Approved Yield Technology, and a Crisis Response After Culper Reframed the Story

ADMA April

ADMA is no longer just a “biotech that is growing.” It is increasingly being priced like a plasma platform with real operating leverage. The key question now is whether the company’s stronger production economics and rising margins are powerful enough to outlast the lingering revenue-quality debate triggered by Culper Research. The balanced but moderately bullish view is that the business has become stronger than the controversy, even if the controversy has not disappeared.

ADMA Biologics, Culper Research, and the revenue quality debate ( $ADMA ) (UPDATED march 27 2026 ADMA Fires Back at Culper)

On March 24, 2026, Culper Research disclosed a short position in ADMA Biologics and published a report arguing that the company’s growth story would be overstated by what it described as a channel stuffing scheme involving rebates, extended payment terms, inventory loading, and an undisclosed related-party distributor. Public summaries of the report say Culper’s central claim is stark: absent the alleged sell-in distortion, ADMA’s 2025 revenue would have declined rather than grown. That was enough to break the prior narrative around ADMA as a premium commercial plasma story with unusually strong operating leverage.

ADMA Biologics ($ADMA) meeting or exceeding guidance Feb25?

ADMA Biologics (NASDAQ: ADMA) is a commercial-stage biopharmaceutical company specializing in plasma-derived immunoglobulins for the treatment of patients with primary humoral immunodeficiency (PI) and others at risk of certain infections. The company operates a fully integrated business model encompassing plasma collection, fractionation, manufacturing and commercialization.

ADMA Adma Biologics Inc

Commercial IG platform with three FDA-approved products, a yield-enhanced manufacturing process, and a revenue ramp from <$200M to >$500M in a handful of years. Not a binary biotech story, but an execution and capacity game that the market is finally treating like a growth compounder.

ADMA BIOLOGICS

ADMA Biologics is a rare biotech company that combines clinical success with financial profitability. Unlike pre-revenue biotech plays, ADMA operates a functioning immunoglobulin (plasma-derived therapy) business generating $426.5M in FY2024 revenue (+65% YoY) with actual net income of $197.7M. The company is well-managed, debt-reducing, and positioned in a high-growth market ($53.5B global plasma therapy market projected by 2033).